Weight & Metabolic Health

Start here

The arrival of GLP-1 drugs has done something unusual: it has produced weight loss results in trials that are large enough to change what is medically possible, while generating a marketing environment that is close to unnavigable.

Both things are true at once, and holding both is the point of this section. Semaglutide and tirzepatide produce weight loss that older drugs never approached. They also come with a set of consequences that the advertising does not mention, an aftermath that most men are unprepared for, and a grey market of compounded copies whose legal basis expired in 2025.

The most important number is not the headline loss. It is what happens afterwards. In the trial that followed people after stopping, participants who had lost 17.3% regained about two-thirds of it within a year, and blood pressure returned to baseline. Net loss was still 5.6%, which is real, and is not what anyone thought they were buying.

That reframes the drug. It is not a course of treatment that ends with a result. It is a long-term medication for a chronic condition, in the same way that a blood pressure tablet is, and the decision should be made on those terms.

What the evidence supports

The weight loss is real and large. The trial data are strong and the effect sizes are unlike anything previously available without surgery.

Stopping reverses most of it. Roughly two-thirds regained within a year, along with the cardiometabolic improvements. This is the single most under-communicated fact in the category.

A meaningful share of the loss is lean tissue: around a quarter to a third, which is roughly proportionate to any large weight loss rather than selective muscle wasting. That distinction matters. It is not a unique failing of these drugs, but 5.6 kg of lean mass is still 5.6 kg, and it does not return on its own when you stop.

Compounded copies are a different product from the approved one. The shortage that made them legal ended, and the legal basis for compounding semaglutide expired in 2025. The FDA has logged around 990 adverse event reports for compounded semaglutide and says they are underreported.

Resistance training and adequate protein are the mitigation for the lean mass question, and they are the part of the protocol that the prescribing process usually leaves out entirely.

Which article you need

Start with what the trials actually show: the effect sizes, the trial populations, the side effects and how the two main drugs compare.

Before you start, read what happens when you stop. It is the article most likely to change your decision, and it is better read before than after.

Do GLP-1s cost you muscle? covers the body composition data and what to do about it.

And if you are considering a cheaper compounded version, what you are actually buying covers the legal position, the dosing errors that have caused harm, and what “compounded” means in practice.

Once you are on one, the real side-effect rates matter more than the summary you were given, nausea affects 44% of people, and two symptoms mean stop and call someone.

If you are choosing between the two main drugs, the head-to-head trial randomised 751 people for 72 weeks and found 20.2% against 13.7%, with the uncomfortable footnote that men lost about 6% less than women on both.

Who actually qualifies covers the BMI thresholds, the absolute contraindications, and the question a legitimate prescriber asks before writing anything.

And the alcohol craving signal is the most interesting unapproved finding in the category: two randomised trials, a real effect, and not yet a basis for treatment.

What else is worth reading

Weight sits upstream of a great deal else on this site. Losing it raises testosterone without a prescription, which makes it one of the few genuinely effective interventions in raising testosterone naturally.

It also improves obstructive sleep apnea, sometimes substantially, and sleep apnea is itself a cause of fatigue, high blood pressure and erectile dysfunction that most men never get tested for.

Because an erection is a blood-flow event, metabolic health shows up there first. What exercise and diet actually achieve for erections covers the trial evidence.

Diabetes and prediabetes screening starts at 35 for men carrying extra weight, which is earlier than most expect. That and the rest of the list are in the health checks worth having.

And if the eating pattern you are trying to interrupt is tied to mood, drinking or sleep rather than appetite alone, the mental health section and the alcohol evidence are the more useful places to start.

Related topics

Metabolic health sits upstream of other sections here: screening and blood pressure in general men’s health, hormones in testosterone and male vitality, and erections in erectile dysfunction.